“Fast acting cyanide antidote discovered...”
That’s great news MamaDearest.
New approach to treating anthrax significantly improves survival
Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that the results of two animal studies demonstrated the life-saving potential of its human monoclonal antibody drug ABthrax(TM) (raxibacumab). The results show that a single dose of ABthrax, administered without concomitant antibiotics, improved survival rates by up to 64 percent when administered after animals were symptomatic for anthrax disease as a result of inhalation exposure to massively lethal doses of anthrax spores. These dramatic and statistically significant findings demonstrate a survival benefit in two animal species, which is the requirement for establishing the efficacy of new drugs used to counter bioterrorism